Literature DB >> 8094010

The role of factor XIIIa-positive dermal dendrocytes in HIV-1-positive psoriatics.

F van Neer1, V Zemelman, R Cerio, J Langtry, R C Staughton.   

Abstract

Factor XIIIa-positive dermal dendrocytes (FXIIIa+ dd) may have an important role in the pathogenesis of psoriasis, in that their numbers are increased in lesional skin compared with non-lesional skin. Moreover, in AIDS-associated Kaposi's sarcoma the number of these cells is also increased, in comparison with the classical type of Kaposi's sarcoma. In addition, patients suffering from HIV-1 infection may develop severe psoriasis. The aim of this study was to examine the distribution of FXIIIa+ dd in lesional and non-lesional skin from seven psoriatic patients with positive HIV-1 serology, and compare the results with age-, sex-, and site-matched HIV-1-negative psoriatic patients. In both patient groups there was an increase of FXIIIa+ dd in the papillary dermis in lesional skin, compared with non-lesional skin (HIV+ [P = 0.007]; HIV- [P = 0.0006]). Positive cells were also observed within the epidermis in lesional skin in both groups. However, there was no significant difference between HIV-1+ and HIV-1- groups in the number of FXIIIa+ dd in the epidermis and dermis (P > 0.05). These findings suggest that, if FXIIIa+ dd do have a role in psoriasis, deterioration of this condition in HIV-1+ patients is not due to proliferation of dermal dendrocytes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094010     DOI: 10.1111/j.1365-2133.1993.tb00142.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  2 in total

1.  Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines.

Authors:  F O Nestle; L A Turka; B J Nickoloff
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

2.  Factor XIII insufficiency in a patient with severe psoriasis vulgaris, arthritis, and infirmity.

Authors:  K Heinle; O Adam; G Rauh
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.